Head-To-Head Survey: GeoVax Labs (GOVX) versus The Competition

GeoVax Labs (NASDAQ:GOVX) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare GeoVax Labs to related businesses based on the strength of its dividends, analyst recommendations, profitability, earnings, institutional ownership, risk and valuation.

Profitability

This table compares GeoVax Labs and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-901.14%	-392.27%
GeoVax Labs Competitors	-12,319.70%	-407.93%	-30.95%

Analyst Recommendations

This is a summary of current ratings and target prices for GeoVax Labs and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1	1	1	0	2.00
GeoVax Labs Competitors	9903	15310	45655	1602	2.54

GeoVax Labs presently has a consensus price target of $3,600.00, indicating a potential upside of 210,426.32%. As a group, “Biotechnology” companies have a potential upside of 102.12%. Given GeoVax Labs’ higher possible upside, equities analysts clearly believe GeoVax Labs is more favorable than its peers.

Valuation & Earnings

This table compares GeoVax Labs and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
GeoVax Labs	$2.49 million	-$21.47 million	-0.15
GeoVax Labs Competitors	$713.66 million	$10.27 million	-18.80

GeoVax Labs’ peers have higher revenue and earnings than GeoVax Labs. GeoVax Labs is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

GeoVax Labs has a beta of 3.85, indicating that its stock price is 285% more volatile than the S&P 500. Comparatively, GeoVax Labs’ peers have a beta of -1.86, indicating that their average stock price is 286% less volatile than the S&P 500.

Institutional & Insider Ownership

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 0.2% of GeoVax Labs shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

GeoVax Labs peers beat GeoVax Labs on 9 of the 13 factors compared.

GeoVax Labs Company Profile

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.